News & Updates

The use of sodium zirconium cyclosilicate (SZC) among patients with heart failure (HF) and reduced ejection fraction (HFrEF) and hyperkalemia has significantly improved the proportion of those with normokalemia while on optimal spironolactone dose, a study has shown.

When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.

Among Asians with type 2 diabetes (T2D), users of sodium-glucose cotransporter-2 (SGLT2) inhibitors may have better kidney outcomes compared with those who use other glucose-lowering drugs.

Treatment with ensitrelvir among household contacts (HHC) of index patients (IP) with COVID-19 within 72 h after the onset of IP symptoms demonstrates efficacy and an acceptable safety profile as postexposure prophylaxis (PEP) in SCORPIO-PEP, a phase III placebo-controlled trial.

A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.